Back to results
US 12,196,756 B2Granted
Lectin-based diagnostics of cancers
AssigneeUniogen Oy
InventorsKamlesh Gidwani, Kim Pettersson, Henna Kekki
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to non-invasive diagnostics of cancers, such as breast cancer, colorectal cancer, pancreatic cancer and prostate cancer, on the basis of altered glycosylation patterns of cancer-associated biomarkers.
Claims12
A method for treating pancreatic cancer in a subject in need thereof, said method comprising:
- (a) assaying a sample obtained from the subject to detect a level of a Carbohydrate antigen 19-9 (CA19-9) glycoform that binds to Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN), wherein the CA19-9 glycoform is CA19-9DC-SIGN, and wherein a CA19-9 specific antibody is used as a capturing agent and DC-SIGN as a detectably labelled tracer, or wherein DC-SIGN is used as a capturing agent and a CA19-9 specific antibody as a detectably labelled tracer;
- (b) comparing the detected level of said CA19-9DC-SIGN in said sample with that of (i) a healthy control sample, (ii) a benign control sample, or (iii) a predetermined threshold value;
- and
- (c) when the detected level of said CA19-9DC-SIGN in said sample is increased compared to that of (i) said healthy control sample, (ii) said benign control sample, or (iii) said predetermined threshold value, treating said subject for said pancreatic cancer with surgery, radiation therapy, chemotherapy, or any combination thereof.
1 more element
Dependencies are inferred from the claim text.